
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
16
1kṀ1142resolved Jan 7
Resolved
YES1D
1W
1M
ALL
The rise of GPL-1 agonists as "miracle" drugs to cure obesity, hypertension, and a myriad of social issues related to an unhealthy body mass has been nothing short of stunning -- as important as the development of AI. But we are just learning about the other potential effects of these. Will a new clinical trial at least confirm what we think we know about this class of drugs?
This question is managed and resolved by Manifold.
Get
1,000 to start trading!
🏅 Top traders
# | Name | Total profit |
---|---|---|
1 | Ṁ32 | |
2 | Ṁ26 | |
3 | Ṁ17 | |
4 | Ṁ14 | |
5 | Ṁ14 |
Sort by:
[deleted]
Related questions
Related questions
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
71% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
86% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
81% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
36% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
17% chance
Before 2033, will semaglutide be shown to improve lifespan, when prescribed to overweight people?
82% chance